Perioperative Management of Systemic Cancer Therapies

23 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Jonathan M. Morris, MD, an Orthopedic Oncologist at Emory University in Atlanta, GA, shares insights from his article appearing in the March 2026 issue of Mayo Clinic Proceedings. In this consensus recommendation, Dr. Morris discusses how the new classes of anti-cancer medications include antibody drug conjugates, T-cell engagers, hormonal therapies, immune checkpoint inhibitors, targeted therapies, and bone modifying agents affect patients undergoing surgery. He notes each drug class presents its own side effect profile, which may play a role in how the drug should be managed in the perioperative setting. Dr. Morris recommends patients should review all medications with their care providers and clinicians should explore the latest developments around side effects for these emerging therapies. Available at: https://mayocl.in/3ZDOtun
Categoria
Oncology
Commenta per primo questo video.

Prossimo